Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology.
Due to the fast growing user interest, but moreover the patient demand for endoscopic spinal surgery, joimax® sees another record in revenues in Q3/2017, with almost 60% of growth year over year, whereas joimax USA is almost doubling its revenues compared to 2016.
WILEX AG today reported on the first nine months of fiscal year 2017 (1 December 2016 – 31 August 2017) and the Group's financial figures.
Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that the Agency has accepted the submission of its New Drug Application (NDA) seeking market approval for Methylene Blue MMX™ (formerly LuMeBlue™) in the United States.
Apogenix AG, ..., announced today that its lead product candidate, asunercept (APG101), has been granted orphan designation from the European Commission (EC) for the treatment of myelodysplastic syndromes (MDS).
Cosmo Pharmaceuticals N.V. today announced that it has entered into an exclusive co-promotion agreement for Eleview™ in the U.S. with Olympus America Inc., a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses.
joimax® announces the grand opening of its new state-of-the-art Training and Education Center in Irvine, California. The company will be holding its first workshop at the Center on September 8-9 th.
Cosmo Pharmaceuticals N.V. reports half-year results for the period ended 30 June 2017.
CureVac AG ..., today announced that the results of CureVac’s phase I clinical trial of its RNActive® prophylactic rabies vaccine was published in the peer-reviewed journal The Lancet.
Cosmo Pharmaceuticals N.V. today announced that its medical device Qolotag® has been granted the CE mark and the approval for marketing in the EU.
Cosmo Pharmaceuticals N.V. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for LuMeBlue® (methylene blue), its drug aimed at enhancing the detection rate of adenomas.
Cassiopea SpA ..., announced today its half-year results for the period ended 30 June 2017.
CureVac AG ..., today announced it has been granted a Notice of Allowance from the European Patent Office (EPO) for its patent application (EP 2958588) entitled, “Combination of Vaccination and Inhibition of the PD-1 Pathway.”
Cosmo Pharmaceuticals N.V. today announced that its licensor, PAION AG today announced that remimazolam, its ultra-short-acting benzodiazepine sedative/anaesthetic, met the primary endpoint and successfully concluded its U.S. Phase III clinical trial in procedural sedation in patients undergoing bronchoscopy.
CureVac AG ... announced during a public open door event at its main location in Tübingen, Germany, on June 24 the extension of its GMP production capabilities to meet the clinical and future commercial needs of its mRNA product pipeline as the company advances towards its goal of bringing the first mRNA product to the market.
WILEX AG today announced that its subsidiary, Heidelberg Pharma GmbH, Ladenburg, Germany, has signed an exclusive multi-target research agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) for the joint development of antibody drug conjugates (ADCs) that use Amanitin as the payload.
CureVac AG ... today announced it has been granted important patents claiming the use of mRNA-based prophylactic vaccines, significantly adding to the Company’s intellectual property (IP) position for its RNActive® Prophylactic Vaccine technology.
Cosmo today announced that Zydus Cadila has informed that the US Food and Drug Administration has given the final approval for Zydus Cadila to market a generic of Lialda® in the US market.
Over the last few weeks, joimax® participated in numerous scientific meetings, held across Europe and Asia. ...
SYGNIS AG today announced changes to the management team and supervisory board. Dr. Heikki Lanckriet (previously Co-CEO) will become sole CEO of SYGNIS AG and will also retain his role as Chief Scientific Officer.
Cosmo today announced that, in order to cope with the group’s increasing growth, it has appointed John Manieri - who joined the Cosmo Group on May 1, 2017 - as Head of Cosmo’s Investor Relation activities and Head of the Investment Committee as of July 1, 2017.
Apogenix AG ... announced today that it has been awarded PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for its lead product candidate, asunercept (APG101), for the treatment of glioblastoma.
Cosmo today announced that in accordance with the explanatory notes to agenda item no. 7 of the next Annual General Meeting (AGM) to be held on 24 May 2017, the shareholders and the board of directors of COSMO Pharmaceuticals N.V. have been provided with the opportunity to recommend a candidate for the position of non-executive board member.
Cosmo Pharmaceuticals N.V. today announced successful results of its randomized, double blind, multicentre, parallel arms clinical trial in the USA and Europe.
Cosmo Pharmaceuticals N.V. today announced that Aries Pharmaceuticals, Inc., the new United States (US) San Diego, California based subsidiary of its 100% subsidiary Aries Pharmaceuticals Ltd., Dublin, has launched Eleview™, for use in gastrointestinal endoscopic procedures in the USA.
SYGNIS AG today reported results for the fiscal year ending December 31, 2016.
joimax® announces 510(k) clearance for its Endovapor® 2 Multi Radio Frequency System during its first presentation at the Annual Scientific Meeting of the American Association of Neurological Surgeons (AANS) 2017, in Los Angeles.
Apogenix AG ... announced today that the company will present at the 13th Annual PEGS ..., UBS – Global Healthcare Conference and Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum.
SYGNIS AG today announced the successful completion of a second contract with TANON, the leading Chinese proteomics company.
joimax ® ,..., just celebrated its 10 years’ birthday in China with an outstanding 3 days event in Chongqing.
Apogenix AG, ..., announced today that a clinical phase I study with ABBV-621 has been initiated by its partner AbbVie.
SYGNIS AG today announced the successful completion of the integration of C.B.S. Scientific Company Inc. (C.B.S.), a profitable life sciences tools company located in San Diego, CA, USA.
Cassiopea S.p.A. , ..., today announced that shareholders approved the financial statements 2016 at the general shareholders meeting in Lainate.
Cosmo Pharmaceuticals N.V. (the “Company”) today announces that Joh. Berenberg, Gossler & Co. KG (“Berenberg”) has placed approximately 1.33 million ordinary shares (“Placing Shares”) in the Company on behalf of certain pre 2007 IPO shareholders, beneficiaries of the employee stock option plan (“ESOP”) and treasury shares of the Company by way of an accelerated book-build offering to qualified investors (the “Placing”).
WILEX AG today published its financial results and annual report for the fiscal year 2016 (1 December 2015 – 30 November 2016) and its outlook for 2017.
Cosmo Pharmaceuticals N.V. today announces that Joh. Berenberg, Gossler & Co. KG (“Berenberg”) intends to place ordinary shares (the “Placing Shares”) in the Company on behalf of certain pre IPO investors, certain beneficiaries of the employee stock ownership plan (“ESOP”), by way of an accelerated book-build offering to qualified investors (the “Placing”).
Cosmo Pharmaceuticals N.V. today announced that it has filed for EU approval of its new medical device named Qolotag.
Two successful phase III clinical trials, Increased operating revenues ..., Proposal for a dividend increased ..., Confident outlook for 2017, significant investments in the US
SYGNIS AG today announced that Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS, will guarantee soft loans from the Spanish government with 500,000 of his SYGNIS shares.
Apogenix, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that comprehensive data on its novel HERA drug candidates will be presented at the upcoming American Society for Cancer Research (AACR) being held April 1-5 in Washington, D.C., USA.
SYGNIS AG today announced the launch of the DNA amplification and validation service TrueAdvance.
SYGNIS AG today announced that the Supervisory Board has resolved important changes and additions to the senior management team to better align the organisational structure with the strategic goals of the Company in terms of corporate growth.
joimax® further ensures its market access in Asia.
Cassiopea SpA, ... today announced the results for the year ended 31 December 2016.
SYGNIS AG today announced the launch of TrueHelix a new bioinformatics service platform, delivered through a dedicated web portal, for Next Generation Sequencing (NGS) providers and customers to analyze their sequencing data.
SYGNIS AG today announced that GBC Research, a German independent research house focusing on listed small and midcap companies, has published a research update on the company.
WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, signed the license agreement with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin covering BCMA antibodies.
CureVac, ... today announced that the European Commission has appointed CureVac’s CEO, Ingmar Hoerr, Ph.D., as one of 15 members of the new High Level Group that will advise the Commission on how to strengthen support for breakthrough, market-creating innovation in Horizon 2020 and future research and innovation programs.
Amgen and Immatics Biotechnologies GmbH, ... today announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers.